December 1, 2023
CHICAGO —Prevent Blindness is announcing the third annual Geographic Atrophy (GA) Awareness Week as Dec. 4-10, 2023. More than eight million people in the world have GA, with an estimated 1 million in the United States, according to the Cleveland Clinic.
Prevent Blindness offers a variety of free, educational resources on GA including a dedicated webpage, expert videos, a comprehensive fact sheet and a series of social media graphics. The fact sheet and graphics are available in English and Spanish. This year’s GA Awareness Week is supported by funding from Apellis Pharmaceuticals, Inc., and Iveric Bio, an Astellas Company.
Additionally, Prevent Blindness is participating in the first World Geographic Atrophy Day on Tuesday, Dec. 5, 2023. The goal of the new initiative is to empower the voices of the global GA community, and provide education, advocacy, and support. World Geographic Atrophy Day is a partnership between BrightFocus Foundation, Fighting Blindness Canada, Macular Society, and Prevent Blindness, and is supported with funding provided by Apellis Pharmaceuticals, Inc.
As part of GA Week at Prevent Blindness, a new episode in the Prevent Blindness Focus on Eye Health Expert Series, “Advancements in Treatments for Geographic Atrophy,” will be available featuring Rajeev S. Ramchandran, MD, MBA, associate professor of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center. Dr. Ramchandran also serves as the volunteer chairperson of the Prevent Blindness Scientific Committee and is a member of its Board of Directors.
Additional Focus on Eye Health Expert Series episodes include “Geographic Atrophy and Patient Support,“ featuring Prevent Blindness Ohio past president and CEO, Sherry Williams, sharing her story as a care partner for her mother diagnosed with GA, and the “Geographic Atrophy” episode, with Janet S. Sunness, MD, medical director of the Richard E. Hoover Low Vision Rehabilitation Services at the Greater Baltimore Medical Center.
GA can lead to progressive and permanent vision loss. Patients with GA in one eye are more likely to develop it in the other eye. There may be no symptoms in the early stages until the disease progresses or affects both eyes.
“The good news is that promising new treatments for GA are now available, with additional options in development,” said Jeff Todd, president and CEO of Prevent Blindness. “By working closely with their eye doctors, people with GA have hope to preserve their vision from the damaging effects of GA.”
For GA and/or AMD patients and their care partners, Prevent Blindness also offers the free resource, Living Well With Low Vision. This program provides a variety of free directories, a library of self-help guides, downloadable apps including “GuideME for AMD,” access to clinical trial research, and recent AMD research news.
